Lymph Node Status after Neoadjuvant Chemoradiation Therapy for Esophageal Cancer according to Radiation Field Coverage.

Conclusion: Radiation therapy for nCRT could downstage clinically suspected nodal metastasis. However, such therapy was ineffective when used to treat nodes that were not suspicious for metastasis. Because significant numbers of residual metastases were identified irrespective of coverage by the radiation field, lymphadenectomy should be performed to ensure complete removal of residual nodal metastases after nCRT. PMID: 31624713 [PubMed]
Source: Korean Journal of Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Tags: Korean J Thorac Cardiovasc Surg Source Type: research

Related Links:

Condition:   Patients With Esophageal Cancer(Ⅱ-Ⅲ) Interventions:   Drug: endostar+chemoradiotherapy;   Other: chemoradiotherapy Sponsor:   Second Affiliated Hospital of Xi'an Jiaotong University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
We conducted risk analyses using the competing risk regression model, which defined death and the development of second malignancies as competing risks. Our study revealed that risk of second primary malignancies was significantly higher compared with the general population. Age, clinical stage, and tumor location were identified as significant factors for the development of second primary malignancies. AbstractBackgroundEsophageal cancer is associated with synchronous or metachronous cancer at other primary sites. However, few studies have evaluated the second malignancies after the treatment of esophageal cancer. The pre...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Circular RNAs (circRNAs), a novel class of noncoding RNAs, have recently drawn much attention in the pathogenesis of human cancers. However, the role of circRNAs in esophageal squamous cell carcinoma (ESCC) re...
Source: Molecular Cancer - Category: Cancer & Oncology Authors: Tags: Research Source Type: research
nimo Isabel Bravo Esophageal cancer (EC) is the seventh most common cancer worldwide and the sixth leading cause of death, according to Globocan 2018. Despite efforts made for therapeutic advances, EC remains highly lethal, portending a five-year overall survival of just 15–20%. Hence, the discovery of new molecular targets that might improve therapeutic efficacy is urgently needed. Due to high proliferative rates and also the limited oxygen and nutrient diffusion in tumors, the development of hypoxic regions and consequent activation of hypoxia-inducible factors (HIFs) are a common characteristic of solid ...
Source: Genes - Category: Genetics & Stem Cells Authors: Tags: Review Source Type: research
k The Cdx2 homeobox gene is important in assigning positional identity during the finely orchestrated process of embryogenesis. In adults, regenerative responses to tissues damage can require a replay of these same developmental pathways. Errors in reassigning positional identity during regeneration can cause metaplasias—normal tissue arising in an abnormal location—and this in turn, is a well-recognized cancer risk factor. In animal models, a gain of Cdx2 function can elicit a posterior shift in tissue identity, modeling intestinal-type metaplasias of the esophagus (Barrett’s esophagus) a...
Source: Genes - Category: Genetics & Stem Cells Authors: Tags: Review Source Type: research
Conditions:   Esophagogastric Cancer;   Esophagus Cancer;   Esophageal Cancer;   Gastric Cancer;   Gastric Adenocarcinoma;   Gastroesophageal Junction Adenocarcinoma;   Gastroesophageal Junction Squamous Cell Carcinoma Interventions:   Drug: 18F-BMS-986229 Injection;   Drug: IV 18F-BMS-986229;   Diagnostic Test: PET/CT Scan Sponsors:   Memorial Sloan Kettering Cancer Center;   Bristol-Myers Squibb Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Drug Safety ; Drug Specificity Intervention:   Drug: Cetuximab-IRDye800 Sponsor:   Fifth Affiliated Hospital, Sun Yat-Sen University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Esophagogastric Cancer;   Esophagus Cancer;   Esophageal Cancer;   Gastric Cancer;   Gastric Adenocarcinoma;   Gastroesophageal Junction Adenocarcinoma;   Gastroesophageal Junction Squamous Cell Carcinoma Interventions:   Drug: 18F-BMS-986229 Injection;   Drug: IV 18F-BMS-986229;   Diagnostic Test: PET/CT Scan Sponsors:   Memorial Sloan Kettering Cancer Center;   Bristol-Myers Squibb Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Drug Safety ; Drug Specificity Intervention:   Drug: Cetuximab-IRDye800 Sponsor:   Fifth Affiliated Hospital, Sun Yat-Sen University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Esophagogastric Cancer;   Esophagus Cancer;   Esophageal Cancer;   Gastric Cancer;   Gastric Adenocarcinoma;   Gastroesophageal Junction Adenocarcinoma;   Gastroesophageal Junction Squamous Cell Carcinoma Interventions:   Drug: 18F-BMS-986229 Injection;   Drug: IV 18F-BMS-986229;   Diagnostic Test: PET/CT Scan Sponsors:   Memorial Sloan Kettering Cancer Center;   Bristol-Myers Squibb Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Esophagectomy | Esophagus Cancer | Heart | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Radiation Therapy | Neoadjuvant Therapy | Radiation Therapy | Women